<i>In Silico</i> Studies of the Hepatitis B Virus Polymerase: Efforts to Identify Novel Drug Binding Sites to Inhibit HBV Replication.

Hepatitis B virus (HBV) replicates via reverse transcription, a reaction catalyzed by the HBV polymerase (P) protein. P is a multidomain protein consists of terminal protein, spacer, reverse transcriptase, and ribonuclease H domains. We used a predicted structural model of HBV P and computationally identified potential non-nucleos(t)ide reverse transcriptase inhibitor (NNRTI) sites. Out of the three potential NNRTI sites, we selected Site 3 for virtual high throughput screening of 837,000 virtual compounds. We selected 53 compounds considering their docking scores, ligand uniqueness, stability and rigidity for screening in HBV replication inhibition assay, but all of them failed to suppress the HBV reverse transcription. Molecular dynamic simulations showed that Site 3 binding pocket is not conformationally stable even after binding of the ligand. This study indicates that additional potential NNRTI sites should be explored, and that rigorous molecular dynamic simulations studies should be performed before virtual compound screening.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-07-16
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Silico Studies of the Hepatitis B Virus Polymerase: Efforts to Identify Novel Drug Binding Sites to Inhibit HBV Replication.

Razia Tajwar, John E. Tavis, Qilan Li
PubMed
Hepatitis B Virus Studies
article

In Silico Studies of the Hepatitis B Virus Polymerase: Efforts to Identify Novel Drug Binding Sites to Inhibit HBV Replication.

Razia Tajwar, John E. Tavis, Qilan Li
article en

Abstract

Hepatitis B virus (HBV) replicates via reverse transcription, a reaction catalyzed by the HBV polymerase (P) protein. P is a multidomain protein consists of terminal protein, spacer, reverse transcriptase, and ribonuclease H domains. We used a predicted structural model of HBV P and computationally identified potential non-nucleos(t)ide reverse transcriptase inhibitor (NNRTI) sites. Out of the three potential NNRTI sites, we selected Site 3 for virtual high throughput screening of 837,000 virtual compounds. We selected 53 compounds considering their docking scores, ligand uniqueness, stability and rigidity for screening in HBV replication inhibition assay, but all of them failed to suppress the HBV reverse transcription. Molecular dynamic simulations showed that Site 3 binding pocket is not conformationally stable even after binding of the ligand. This study indicates that additional potential NNRTI sites should be explored, and that rigorous molecular dynamic simulations studies should be performed before virtual compound screening.

PubMedVol. 123(2)
Saint Louis University (US)
Good health and well-being
Openalex Percentile: Top 43%
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.